Work

Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Patients with AML.

Year: 2005

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v106.11.404.404

Authors: Richard M. Stone, Thomas Fischer, Ronald Paquette, Gary Schiller, Charles A. Schiffer, Gerhard Ehninger, Jorge Cortes, Hagop Kantarjian, Daniel A. DeAngelo, Richard Yu, Lei Zhang, Pamela S. Cohen, Yanfeng Wang, Penny Phillips, Francis Giles

Institutions: Dana-Farber Cancer Institute, University Medical Center of the Johannes Gutenberg University Mainz, Ronald Reagan UCLA Medical Center, UCLA Medical Center, The Barbara Ann Karmanos Cancer Institute, University Hospital Carl Gustav Carus, The University of Texas MD Anderson Cancer Center, Novartis (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4232010039

FWCI: 2.923

Cites:

Cited by: 32

Related to: 10